All In Biotech

NDA 208259 · Alcon Labs INC

Rocklatan

Latanoprost, Netarsudil Dimesylate · Ophthalmic · Prostaglandin Analog

Last checked: Nov 19, 2026Latest source record: Jan 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Mar 12, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

253

56 Phase 3, 9 recruiting

FAERS reports

967

205 serious, 45 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 27, 2026.

1. INDICATIONS AND USAGE ROCKLATAN is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ROCKLATAN ® is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ( 1 )

Mechanism: ROCKLATAN is comprised of two components: netarsudil and latanoprost. Each of these two components decreases elevated IOP. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and glaucomatous visual field loss. ROCKLATAN is believed to reduce IOP by increasing the outflow of aqueous humor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 12, 2019 Original approval · New Combination and New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • ROCKLATAN · LATANOPROST 0.005%; NETARSUDIL DIMESYLATE EQ 0.02% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Latanoprost" as an intervention, any sponsor and status, largest first.

All 253 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ocular hyperaemia149
  • eye irritation115
  • vision blurred102
  • conjunctival hyperaemia94
  • eye pain88
  • lacrimation increased79
  • product dose omission issue76
  • eye pruritus64
  • drug ineffective42
  • death38
  • intraocular pressure increased35
  • fatigue32

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
201959
2020151
202181
202278
2023105
2024166
2025188
2026138

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rocklatan (Netarsudil Mesylat/Latanoprost)

2024 spending

$167M

Beneficiaries

78,022

329,580 claims

Per beneficiary

$2,146

$132.88 per unit

View as table
YearSpending
2020$49,651,592
2021$83,890,591
2022$118,576,611
2023$146,478,267
2024$167,398,355

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 635 on PubMed

Sponsor: Alcon Labs INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.